Britain and America have reached a significant bilateral deal that will keep zero levies on UK pharmaceutical products going into the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to boost funding on pharmaceuticals through the National Health Service (NHS). This move ensures that import taxes on these key exports will stay at zero for a period of the next three years.
This development follows earlier warnings to hike tariffs on branded pharmaceutical products, with figures floated reaching double the cost.
"This agreement with the United Kingdom bolsters the global environment for new treatments and brings long-overdue balance to transatlantic medicine commerce," an announcement said.
Trade Importance
Pharmaceuticals represent one of the Britain's largest exports to the United States, which is easily the primary destination for major companies like GSK and AstraZeneca.
Statistics show that in the 12 months to the end of the third quarter, the UK exported medicines valued at £11.1bn to the US. This figure accounted for 17.4% of British export trade in that span.
"This agreement protects jobs, stimulates capital expenditure and facilitates the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The deal involves several key commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall public funding on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the coming ten years.
- Rebate Cap: The amount manufacturers must pay back to the NHS to stay within budget will be limited at fifteen percent. Previously, repayments were more than twenty percent.
Broader Context
This agreement comes amid a protracted dispute between the drug companies and the ministers over medicine costs and approval rates.
This friction were exacerbated by assertions that American consumers were paying several times more for the identical medicines than people in the UK and Europe.
In recent months, several major pharmaceutical investments in the UK have been halted or cancelled, while major investments have been announced toward projects in the United States.
A senior figure stated that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the past decade.
